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Fig 1. Nonuremic calciphylaxis in a patient treated with
teriparatide: livedoid erythema and retiform purpura on
the bilateral thighs.
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Nonuremic calciphylaxis in a patient with
rheumatoid arthritis and osteoporosis treated
with teriparatide
To the Editor: Calciphylaxis is a devastating condition
in which metastatic calcification of the microvascu-
lature results in thrombosis and ischemic necrosis of
target tissues.1-3 Calciphylaxis is well described
in patients with chronic kidney disease and second-
ary hyperparathyroidism, however the literature
describing it in the absence of these classic comor-
bidities is scant.
A 66-year-old woman presented with a 3-month
history of painful lower extremity nodules. Her
medical history included obesity, pulmonary
emboli, osteoporosis, and a 20-year history of well-
controlled rheumatoid arthritis. Medications
included leflunomide, prednisone (2 mg daily),
warfarin, and teriparatide [recombinant human
Open access under CC BY-NC-ND license.parathyroid hormone (1-34)], initiated 5 months
prior. Physical examination revealed a 10- 3 3-cm
indurated subcutaneous plaque with livedoid ery-
thema and retiform purpura on the bilateral thighs
and scattered indurated subcutaneous nodules on
the bilateral lower extremities (Fig 1). A lateral thigh
lesion was biopsied at an outside facility 2 months
prior, leaving a nonhealing ulcer despite appropriate
wound care. The biopsy specimen was consistent
with thrombotic vasculopathy; however, no addi-
tional workupwas performed. Von Kossa stains were
ordered and read by our pathologist, but no changes
of early calciphylaxis were seen. Laboratory studies
demonstrated normal renal function, parathyroid
hormone levels, and calcium-phosphate product.
Serum and urine protein electrophoresis, antineu-
trophil cytoplasmic antibodies, antinuclear anti-
bodies, and antiphospholipid antibodies were all
negative.
Because of the patient’s multiple risk factors,
calciphylaxis was suspected clinically. Warfarin and
teriparatide were discontinued and the patient was
placed on low-molecular-weight heparin. Given her
risk for poor wound healing, repeated biopsy was
deferred. Bone scintigraphy of the thighs showed no
abnormal uptake. Because of continued clinical
suspicion and further lesion progression, the patient
consented to repeated biopsy. Histopathology re-
vealed intramural calcium deposition in subcutane-
ous arterioles with intimal hyperplasia and ischemic
changes of the surrounding tissue consistent with
calciphylaxis (Fig 2). Treatment with intravenous
sodium thiosulfate therapy was initiated after
surgical consultants determined the patient was a
poor candidate for debridement. Unfortunately, her
lesions progressed over the next month causing
Fig 2. Nonuremic calciphylaxis in a patient treated with
teriparatide: intramural calcium deposition (white arrow)
in subcutaneous arterioles with intimal hyperplasia (black
arrow) and ischemic changes of the surrounding tissue.
(Hematoxylin-eosin stain; original magnification: 3100.)
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cialists. Ultimately, she was transitioned to hospice
care and died soon thereafter.
This case underscores the importance of high
clinical suspicion and prompt diagnosis in patients
presenting with livedoid erythema, painful indurated
subcutaneous plaques, and ulcerations in adipose-
rich areas who have risk factors for nonuremic
calciphylaxis including female gender, obesity,
chronic inflammation, liver disease, rapid weight
loss, malignancy, and primary hyperparathyroid-
ism.1 Corticosteroids,1 warfarin,1 and teraparatide2
have all been implicated as well. These factors
are all thought to disrupt the balance between
nuclear factor-kappa beta (NFB)-mediated activa-
tion and fetuin-A and matrix Gla-protein-mediated
(MGP) inhibition of endothelial cell calcification.3
Because of the patient’s multiple risk factors for
calciphylaxis, the relationship to teriparatide cannot
be stated with certainty, however previous cases
exist.2,4
Calciphylaxis may be diagnosed clinically in
patients with typical skin findings and multiple risk
factors. Because histopathology is often nondiag-
nostic in calciphylaxis, the benefits of a biopsy must
be weighed against the risk of poor wound healing.
If biopsy is performed, special stains may aid in
diagnosis as histopathologic changes of early calci-
phylaxis are subtle.5 Clearer definition of diagnostic
criteria for calciphylaxis is needed.
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Alcohol-induced vasculitis: Case report and
commentary
To the Editor:A26-year-oldwomanwithno significant
medical history on no medications or supplements
was evaluated for a 2-year history of episodic tender,
nonpruritic, purpuric macules and papules on the
back of her feet and legs with associated edema. She
reported that several hours after drinking beer, wine,
or liquor, she develops purpuric lesions (Fig 1) that
resolved within 2 to 7 days without sequelae. She had
experienced at least 8 episodes, eachdirectly linked to
alcohol ingestion. She had no skin lesions in the 6
months before evaluation duringwhich she abstained
from drinking any alcohol.
A provocation test consisted of drinking 8 oz of
alcohol. Within 6 hours she developed subtle pink
macules and papules on her legs. Eight hours after
ingestion, 1 of these lesions was biopsied and
revealed a perivascular neutrophilic infiltrate and
leukocytoclasia with focal vascular wall damage and
fibrinoid changes (Fig 2). On direct immunofluores-
cence, 1 small superficial dermal vessel demonstrated
granular perivascular staining with IgA (not shown).
Four cases of alcohol-associated purpura have
been reported in the literature1-4; none of these
cases included biopsy evidence of vascular wall
damage. Alibrandi et al1 reported a case of a
60-year-old man with recurrent asymptomatic
